938 results on '"Wu Y"'
Search Results
2. P2.03-02 Hybrid Immuno-RT (EclipseRT) for Bulky Tumors: Low-Dose Radiotherapy with Partial Tumor SBRT in Mice and Patients
3. P2.12-08 Response to Emerging Targeted Therapies and Genomic Analysis for NSCLC with Leptomeningeal Metastases and Uncommon Mutations
4. MA06.11 Lorlatinib for Previously Treated ALK-positive Advanced NSCLC: Updated Efficacy and Safety Data from a Phase 2 Study in China
5. P2.03-05 Clinical Impact of Genomic Characterization in Induced Oligometastatic Non-small Cell Lung Cancer
6. P1.27-05 Two- and Three-dimensional Radiomic Measurements for Clinical Stage IA Lung Adenocarcinoma: Less is More
7. P2.04-03 EGRET: First-in-human Study of the Novel Antibody-drug Conjugate AZD9592 ± Anti-cancer Agents in Advanced Solid Tumours
8. EP08.01-02 Single-Cell RNA Sequencing Reveals Unique Immune Landscape in Rare-Mutant Non-Small Cell Lung Cancer Undergoing Chemo-Immunotherapy
9. P2.05-16 Immune Suppressive Microenvironment in Liver Metastases Contributes to Organ-Specific Response of Immunotherapy
10. P1.26-03 Retrospective Comparison of Robotic- and Video-assisted Thoracic Surgery after Neoadjuvant Therapy for Non-small Cell Lung Cancer
11. P1.22-03 Ventana ALK (D5F3) Immunohistochemistry Improves the Accuracy of Pathologic Assessment after Neoadjuvant ALK-TKIs for ALK-Positive NSCLC
12. EP09.04-02 Preoperative Circulating Tumor DNA Status Predicts Pathological Response in Advanced Non-small Cell Lung Cancer
13. P1.27-03 Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis
14. P2.06-07 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)
15. EP08.01-01 Subtyping EGFR-mutated NSCLC Patients with Adjuvant TKIs or Chemotherapy Using Deep Radiomic Signatures
16. OA21.05 Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
17. P1.23-09 Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study
18. MA13.08 Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations
19. P1.02-02 Co-inhibition of MEK/RTKs Pathways via Trametinib Plus Anlotinib forKRAS-Mutant NSCLC
20. P2.10-15 Correlation Between Clinical and Health-related Quality-of-Life (HRQoL) Benefits in Patients With ALK+ NSCLC in ALTA-1L
21. P2.06-03 Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients
22. P1.03-01 Dynamic Transcriptomic Characterization Changes of Early Stage Lung Adenocarcinoma as per the Incrassation of Consolidation Tumor Ratio
23. P1.09-02 Midkine Dependent Immunosuppressive Environment in Cerebrospinal Fluid May Promote Leptomeningeal Metastases of EGFR mutant NSCLC
24. 20P Efficacy and safety of AZD3759 in previously untreated EGFR-mutant non-small cell lung cancer with central nervous system metastases in a multi-center, phase II umbrella trial (CTONG1702)
25. 22P Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trial
26. 197P Combining stereotactic body radiation and low-dose radiation (EclipseRT) with PD-1 inhibitor in mice models and patients with bulky tumor
27. PP01.47 HERTHENA-Lung02: A Randomized Phase 3 Study of Patritumab Deruxtecan vs Platinum-Based Chemotherapy in Locally Advanced or Metastatic EGFR-Mutated NSCLC After Progression with a Third-Generation EGFR TKI
28. PPD02.03 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Analysis of All Patients From VISION Cohorts A and C
29. OA01.09 Adjuvant Osimertinib in Resected EGFR-Mutated Stage IB–IIIA Non-Small Cell Lung Cancer: Updated ADAURA Results
30. PPD02.02 Tepotinib + Gefitinib in Patients with EGFR-Mutant NSCLC with MET Amplification (METamp): Final Analysis of INSIGHT
31. EP08.02-049 A Phase I Trial of the HER2 Exon 20 Inhibitor, BI 1810631, In Patients With Advanced Solid Tumors With HER2 Aberrations
32. EP08.02-039 An Effective Treatment for EGFR-mutated Lung Adenocarcinoma with Symptomatic Leptomeningeal Metastases Using Aumolertinib
33. EP08.01-085 Sintilimab versus Pembrolizumab as Monotherapy or in Combination with Chemotherapy for Treatment Naïve Metastatic Non-small Cell Lung Cancer
34. EP10.01-010 Real-world Study of the Incidence and Risk Factors of Venous Thromboembolism in Chinese Lung Cancer (RIVAL)
35. OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer
36. EP08.02-156 Real-World Treatment Patterns and Impact of Comorbidity Burden on Treatment Duration for Patients with ALK+ NSCLC in the US
37. EP08.01-080 Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced NSCLC in Patients aged ≥ 70
38. EP08.01-071 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Non-Squamous NSCLC
39. EP16.02-024 Plasma ctDNA Organ-Specific Genomic Patterns and Origination Analysis in Advanced Non-Small Cell Lung Cancer
40. EP08.01-070 Safety and Efficacy of Sitravatinib + Tislelizumab in Patients with PD-L1+, Locally Advanced/Metastatic, Squamous NSCLC
41. EP02.01-012 PD-L1 Expression Predicts Prognosis in Completely Resected NSCLC Patients with an EGFR Mutation
42. EP08.02-108 Osimertinib Long-Term Tolerability in Patients with EGFRm NSCLC Enrolled in the AURA Program or FLAURA Study
43. EP08.02-064 ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
44. EP08.02-063 SANOVO: A Phase 3 Study of Savolitinib or Placebo in Combination with Osimertinib in Patients with EGFR-mutant and MET Overexpressed NSCLC
45. EP16.01-025 Immune Evolution of Metastases & Underlying Molecular Mechanisms in Non-small Cell Lung Cancer
46. OA02.05 Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study
47. OA03.05 Tepotinib in Patients with MET Exon 14 (METex14) Skipping NSCLC: Primary Analysis of the Confirmatory VISION Cohort C
48. EP01.07-005 Combined Diffusion-Weighted Imaging and Dynamic Contrast-Enhanced MRI for Diagnosing Indeterminate Pulmonary Nodules
49. MA02.05 Dynamic Mutation Profiles of SCLC Transformation in NSCLC Patients Harboring Concurrent EGFR/TP53/RB1 Mutations
50. P4.17F.05 Adherence to Clinical Practice Guideline - Analysis of 89 Multidisciplinary Team Discussed Patients with Stage III Lung Cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.